Results 291 to 300 of about 597,687 (362)

Correction: Uncovering drug targets for cluster headache through proteome-wide Mendelian randomization analysis

The Journal of Headache and Pain
Zhonghua Xiong, Zhi Guo, Lei Zhao, Dong Qiu, Yanliang Mei, Xiaoshuang Li, Peng Zhang, Mantian Zhang, Geyu Liu, Tianshuang Gao, International Consortium for Cluster Headache Genetics, Yonggang Wang, Xueying Yu   +12 more
doaj   +1 more source

Which Exercise Patterns Are Most Effective for Reducing Severe Headache/Migraine in Adults? Evidence From a Nationally Representative U.S. Sample. [PDF]

Am J Lifestyle Med
Wang Y, Zhu X, Liang Y.
europepmc   +1 more source

The National Academies’ 2024 Diagnostic Criteria for Long COVID: Concerns That Could Affect the Rheumatology Community

Arthritis &Rheumatology, EarlyView.
Leonard H. Calabrese, Michael Putman, Jeffrey A. Sparks, Zachary Wallace, Alfred H. J. Kim, Kevin L. Winthrop, Cassandra Calabrese   +6 more
wiley   +1 more source

First‐in‐human safety, tolerability, pharmacokinetics and pilot food‐effect study of the candidate antimalarial compound MMV367

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim To evaluate the safety, tolerability and pharmacokinetics in healthy participants of orally administered MMV367 (GSK3772701), a novel antimalarial interfering with Plasmodium falciparum acyl coenzyme A synthetase 10/11 function. Methods This first‐in‐human study enrolled 47 healthy male and female participants.
Andrea Kuemmerle, Nand Singh, Denis Gossen, Annick Janin, Raman Sharma, Anthony Cahn, Rachel A. Gibson, Somasekhara R. Menakuru, Erin Lambourne, Tom Dove, Francisco‐Javier Gamo, Laura Sanz, Benoit Bestgen, Stephan Chalon   +13 more
wiley   +1 more source

Migraine Headache and Its Related Disability Factors Among University Students in Jordan: A Cross-Sectional Study. [PDF]

J Pain Res
Almomani MA, Almomani BA, Al-Sawalha NA, Alqudah AA.   +3 more
europepmc   +1 more source

Assessment of ethnic differences in pharmacokinetics and clinical responses of acalabrutinib between Chinese and White patients with B‐cell malignancies

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims The aim of this study was to assess differences between Chinese and White patients in pharmacokinetics (PK) of, and clinical response to, acalabrutinib and its pharmacologically active major metabolite, ACP‐5862, to support recommended dosing in Chinese patients with B‐cell malignancies.
Tingting Yao, Junjie Ding, Shringi Sharma, Yunfei Li, Qianwei Xu, Peiming Ma   +5 more
wiley   +1 more source

Migraine triggers, phases, and classification using machine learning models. [PDF]

Front Neurol
Reddy A, Reddy A.
europepmc   +1 more source

Safety and effectiveness of the anti‐amyloid monoclonal antibody (mAb) drug lecanemab for early Alzheimer's disease: The pharmacovigilance perspective

British Journal of Clinical Pharmacology, Volume 91, Issue 5, Page 1352-1360, May 2025.
Abstract The development of humanized IgG1 anti‐amyloid monoclonal antibodies, such as lecanemab, provides a promising novel treatment pathway with potential disease‐modifying effects for patients with early Alzheimer's disease (AD). Lecanemab, which gained marketing approval by the United States Food and Drug Administration (US FDA) in July 2023, has ...
Amy Bobbins, Miranda Davies, Elizabeth Lynn, Debabrata Roy, Alison Yeomans, Saad A. W. Shakir   +5 more
wiley   +1 more source

Differences in pharmacological migraine treatment across different levels of clinical headache care - a cross-sectional study. [PDF]

J Headache Pain
Fitzek MP, Overeem LH, Ulrich M, Hong JB, Hoehne CL, Lange KS, Salim Y, Reuter U, Raffaelli B.   +8 more
europepmc   +1 more source

A Case of Wallenberg Syndrome Presenting With Thunderclap Headache and Delayed Diagnosis Due to Negative Findings on Two MRI Examinations. [PDF]

Cureus
Nozaki Y, Yamamoto M, Demura K, Sakakibara Y.   +3 more
europepmc   +1 more source